115 related articles for article (PubMed ID: 23192228)
1. Lack of either estrogen or progesterone receptor expression is associated with poor survival outcome among luminal A breast cancer subtype.
Park S; Park BW; Kim TH; Jeon CW; Kang HS; Choi JE; Hwang KT; Kim IC
Ann Surg Oncol; 2013 May; 20(5):1505-13. PubMed ID: 23192228
[TBL] [Abstract][Full Text] [Related]
2. Retrospective analysis of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor-2 (HER2), Ki67 changes and their clinical significance between primary breast cancer and metastatic tumors.
Qi G; Zhang X; Gai X; Yan X
PeerJ; 2024; 12():e17377. PubMed ID: 38766488
[TBL] [Abstract][Full Text] [Related]
3. PROGNOSTIC IMPACT OF LOW ESTROGEN AND PROGESTERONE POSITIVITY IN LUMINAL B (HER2 NEGATIVE) BREAST CANCER.
Rajc J; Fröhlich I; Mrčela M; Tomaš I; Flam J
Acta Clin Croat; 2018 Sep; 57(3):425-433. PubMed ID: 31168174
[TBL] [Abstract][Full Text] [Related]
4. The clinical value of progesterone receptor expression in luminal breast cancer: A study of a large cohort with long-term follow-up.
Lashen AG; Toss MS; Mongan NP; Green AR; Rakha EA
Cancer; 2023 Apr; 129(8):1183-1194. PubMed ID: 36653923
[TBL] [Abstract][Full Text] [Related]
5. Pattern of recurrence of early breast cancer is different according to intrinsic subtype and proliferation index.
Ribelles N; Perez-Villa L; Jerez JM; Pajares B; Vicioso L; Jimenez B; de Luque V; Franco L; Gallego E; Marquez A; Alvarez M; Sanchez-Muñoz A; Perez-Rivas L; Alba E
Breast Cancer Res; 2013; 15(5):R98. PubMed ID: 24148581
[TBL] [Abstract][Full Text] [Related]
6. Single Hormone Receptor-Positive Metaplastic Breast Cancer: Similar Outcome as Triple-Negative Subtype.
Mao J; Hu J; Zhang Y; Shen J; Dong F; Zhang X; Ming J; Huang T; Run X
Front Endocrinol (Lausanne); 2021; 12():628939. PubMed ID: 33972826
[TBL] [Abstract][Full Text] [Related]
7. Correlations between Tumor to Background Ratio on Breast-Specific Gamma Imaging and Prognostic Factors in Breast Cancer.
Lee SJ; Choi YY; Kim C; Chung MS
J Korean Med Sci; 2017 Jun; 32(6):1031-1037. PubMed ID: 28480663
[TBL] [Abstract][Full Text] [Related]
8. Agreement of self-reported hormone receptor status with cancer registry data in young breast cancer patients.
McCarthy AM; McGuire E; Bristol M; Fredricks T; Domchek SM; Armstrong K
Cancer Epidemiol; 2013 Oct; 37(5):601-5. PubMed ID: 23810747
[TBL] [Abstract][Full Text] [Related]
9. Effects of clinicopathological factors on prognosis of young patients with resected breast cancer.
Li W; Deng Y; Wu Q; Chen W; Liu Z; Wang T; Ai C; Chen F; Wang Z; Ma G; Zhou Q
Medicine (Baltimore); 2021 Feb; 100(5):e23693. PubMed ID: 33592828
[TBL] [Abstract][Full Text] [Related]
10. Are breast cancer molecular classes predictive of survival in patients with long follow-up?
Pracella D; Bonin S; Barbazza R; Sapino A; Castellano I; Sulfaro S; Stanta G
Dis Markers; 2013; 35(6):595-605. PubMed ID: 24288429
[TBL] [Abstract][Full Text] [Related]
11. ER+/PR- phenotype exhibits more aggressive biological features and worse outcome compared with ER+/PR+ phenotype in HER2-negative inflammatory breast cancer.
Luo Y; Li Q; Fang J; Pan C; Zhang L; Xu X; Qian S; Zhao X; Hou L
Sci Rep; 2024 Jan; 14(1):197. PubMed ID: 38167641
[TBL] [Abstract][Full Text] [Related]
12. Significance of Estrogen/Progesterone Receptor Expression in Metaplastic Breast Carcinoma.
Hashmi AA; Mallick BA; Rashid K; Malik UA; Zia S; Zia F; Irfan M
Dis Markers; 2024; 2024():2540356. PubMed ID: 38601434
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological features and survival outcomes of luminal-like breast tumors with estrogen receptor loss at metastatic recurrence: A case-control study.
Morganti S; Marra A; Gandini S; Ascione L; Ivanova M; Venetis K; Sajjadi E; Zagami P; Giugliano F; Taurelli Salimbeni B; Berton Giachetti PPM; Corti C; De Camilli E; Curigliano G; Fusco N; Criscitiello C
Eur J Cancer; 2023 Dec; 195():113397. PubMed ID: 37890353
[TBL] [Abstract][Full Text] [Related]
14. Progesterone receptor status and Ki-67 index may predict early relapse in luminal B/HER2 negative breast cancer patients: a retrospective study.
Zong Y; Zhu L; Wu J; Chen X; Huang O; Fei X; He J; Chen W; Li Y; Shen K
PLoS One; 2014; 9(8):e95629. PubMed ID: 25170613
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical expression of substance P in breast cancer and its association with prognostic parameters and Ki-67 index.
Al-Keilani MS; Elstaty RI; Alqudah MA; Alkhateeb AM
PLoS One; 2021; 16(6):e0252616. PubMed ID: 34086748
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological significance of ATM-Chk2 expression in sporadic breast cancers: a comprehensive analysis in large cohorts.
Abdel-Fatah TM; Arora A; Alsubhi N; Agarwal D; Moseley PM; Perry C; Doherty R; Chan SY; Green AR; Rakha E; Ball G; Ellis IO; Madhusudan S
Neoplasia; 2014 Nov; 16(11):982-91. PubMed ID: 25425972
[TBL] [Abstract][Full Text] [Related]
17. HER2-Low Breast Cancer: Incidence, Clinicopathologic Features, and Survival Outcomes From Real-World Data of a Large Nationwide Cohort.
Baez-Navarro X; van Bockstal MR; Andrinopoulou ER; van Deurzen CHM
Mod Pathol; 2023 Apr; 36(4):100087. PubMed ID: 36788086
[TBL] [Abstract][Full Text] [Related]
18. Progesterone receptor assembly of a transcriptional complex along with activator protein 1, signal transducer and activator of transcription 3 and ErbB-2 governs breast cancer growth and predicts response to endocrine therapy.
Díaz Flaqué MC; Galigniana NM; Béguelin W; Vicario R; Proietti CJ; Russo R; Rivas MA; Tkach M; Guzmán P; Roa JC; Maronna E; Pineda V; Muñoz S; Mercogliano M; Charreau EH; Yankilevich P; Schillaci R; Elizalde PV
Breast Cancer Res; 2013 Dec; 15(6):R118. PubMed ID: 24345432
[TBL] [Abstract][Full Text] [Related]
19. Agreement between molecular subtyping and surrogate subtype classification: a contemporary population-based study of ER-positive/HER2-negative primary breast cancer.
Lundgren C; Bendahl PO; Borg Å; Ehinger A; Hegardt C; Larsson C; Loman N; Malmberg M; Olofsson H; Saal LH; Sjöblom T; Lindman H; Klintman M; Häkkinen J; Vallon-Christersson J; Fernö M; Rydén L; Ekholm M
Breast Cancer Res Treat; 2019 Nov; 178(2):459-467. PubMed ID: 31432367
[TBL] [Abstract][Full Text] [Related]
20. Effect of tumor size on breast cancer-specific survival stratified by joint hormone receptor status in a SEER population-based study.
Zheng YZ; Wang L; Hu X; Shao ZM
Oncotarget; 2015 Sep; 6(26):22985-95. PubMed ID: 26036636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
